News

Investment

TruDiagnostic and NADMED partner on new NAD blood diagnostic

Longevity investment bulletin: Celmatix, BlueRock, TruDiagnostic and more

New data suggest investigational osteoarthritis drug may have promising senotherapeutic effect

AKL’s investigational oral osteoarthritis drug APPA may have a dual effect on senescence with potential in other diseases of aging.

Retro: A longevity biotech triple-threat?

Cyclarity: When bad guy cells have a change of heart

Stressed tissue and cellular burn-out? Enter the Mitochondrial Cycle

Cambrian Bio reveals new pipeline company with focus on AMPK activation

Longevity investment bulletin: Remedium Bio, GenSight Biologics, SomaLogic and more

First longevity clinical study design fetches FDA approval

Longevity investment bulletin: ChromaDex, Nightingale Health, Capsida and more

OpenAI CEO invested $180 million in longevity company Retro Bio

Meet the Founder: Yuri Deigin

MitoRx announces Scientific Advisory Board as its ASA enters final few weeks.

Plant-derived osteoarthritis drug ready for further Phase 2 trials

Longevity investment bulletin: Assured Allies, Fountain Life, Form Bio and more

Longevity company Biophysical Therapeutics emerges from stealth

Longevity investment bulletin: Longeveron, EVERMIND, Longevity Labs and more

How the longevity industry can deliver lives that are healthier – physically and mentally

Leonhardt Ventures and Lionheart Health file patent for bioelectric control of antiaging protein expression

Longevity investment bulletin: Five Alarm Bio, Capsida, MyMD and more

Causeway Therapeutics secures £8.75 million for Phase 2 trial of tendinopathy therapy

Longevity investment bulletin: Impact funds, Lineage Cell Therapeutics and Maximon

Longevity investment bulletin: Athersys, Maze, TreeFrog and more

Longevity investment bulletin: Cerevance, Frequency, Heartseed, Life Biosciences and more

Longevity investment bulletin: Insilico Medicine, Biophytis, Synartro and more

Making a noise about the silent killer

Cambrian BioPharma unveils new pipeline company

Biosplice announces data from osteoarthritis clinical trial – and the initiation of new phase 3 trial

Occuity look to pet longevity, targeting diabetes management in pets

Fountain Life announces $15 million investment

Sound opportunity: Hearing Diagnostics £1.1m funding augurs market breakthrough

Constructively disruptive – tackling atherosclerosis through disease reversal

Find us here ...

Subscribe to our newsletter

© Copyright 2022 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.